Caligor Opco Selected to Support Puma Biotechnology’s Managed Access Program for Neratinib Outside the United States

Secaucus, N.J., December 15, 2016

Caligor Opco LLC, which specializes in early access to medicines and drug life-cycle management, is partnering with Puma Biotechnology (NYSE: PBYI) to implement and oversee the company’s Managed Access Program for PB272 (neratinib). Managed access programs provide physicians and patients access to medicines when there are limited or no other therapeutic options available.
Continue reading